Berberine Induces p53-Dependent Apoptosis through Inhibition of DNA Methyltransferase3b in Hep3B Cells

김대연,; 김선형,; 정희태,; 라창식,; 이기종,; 정배동,

doi:10.15324/kjcls.2020.52.1.69

Cited by 6 publications

(3 citation statements)

References 37 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DNMT affects the methylation of several genes, including p53, a tumor suppressor gene 33 - 36 . p53 protein is not expressed in Hep3B cells; however, inhibition of DNMT expression induces p53 protein expression 37 . DNA demethylation caused by 5-aza activates the p53 signaling pathway and induces apoptosis 35 .…”

Section: Discussionmentioning

confidence: 98%

Effect of 5-azacytidine (5-aza) on UCP2 expression in human liver and colon cancer cells

Kim¹,

Cheong²,

Ra³

et al. 2021

Int. J. Med. Sci.

Self Cite

View full text Add to dashboard Cite

The function of the uncoupling protein 2 (UCP2) is different for each cancer cell. However, the mechanism of expression is still unclear. DNA methylation affects protein expression and is one factor that transforms normal cells into cancer cells. In this study, the hepatocellular carcinoma Hep3B and HepG2 cells and colorectal cancer HT-29 cells were treated with 5-azacytidine (5-aza), a DNA demethylation agent, to observe the modification of UCP2 expression and the methylation degree in the UCP2 promoter region. Promoter basal activity and degree of UCP2 expression were measured in Hep3B, HepG2, and HT-29 cells. In addition, methylation-specific PCR (MSP) was performed to investigate the degree of methylation in the UCP2 promoter region. The methylation region in the UCP2 promoter was confirmed based on bisulfite sequencing. In Hep3B cells in which UCP2 mRNA was not transcribed, the promoter basal activity was significantly higher than in HT-29 or HepG2 cells in which UCP2 mRNA was transcribed. Treatment with 5-aza increased UCP2 expression in Hep3B and HT-29 cells; however, the expression in HepG2 cells was unchanged. The UCP2 promoter in Hep3B cells has numerous methylated regions compared with HT-29 and HepG2 cells. The results of the present study revealed that inhibition of UCP2 expression in Hep3B cells was due to methylation of the promoter region. Investigating the mechanism that induces UCP2 expression in cancer cells is important to understand the function of UCP2, which could aid in cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 98%

Effect of 5-azacytidine (5-aza) on UCP2 expression in human liver and colon cancer cells

Kim¹,

Cheong²,

Ra³

et al. 2021

Int. J. Med. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…DNMT affects the methylation of several genes, including p53, a tumor suppressor gene [35][36][37][38]. p53 protein is not expressed in Hep3B cells; however, inhibition of DNMT production induces p53 protein expression [39]. DNA demethylation caused by 5-aza activates the p53 signaling pathway and induces apoptosis [37].…”

Section: Discussionmentioning

confidence: 99%

Treatment with 5-azacytidine Increases UCP2 levels in Hep3B and HT-29 Cells but Not in HepG2 Cells

Kim¹,

Jung²,

Cheong³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The function of the uncoupling protein 2 (UCP2) is different for each cancer cell, and the mechanism of production is unclear. DNA methylation affects protein expression and is one factor that transforms normal cells into cancer cells. The hepatocellular carcinoma Hep3B and HepG2 cells and colorectal cancer HT-29 cells were treated with 5-azacytidine (5-aza), a DNA demethylation agent, to observe the modification of UCP2 production and the methylation degree in the UCP2 promoter region.Methods: Promoter basal activity and degree of UCP2 production were measured in Hep3B, HepG2, and HT-29 cells. In addition, methylation-specific PCR (MSP) was performed to investigate the degree of methylation in the UCP2 promoter region. The methylation region in the UCP2 promoter was confirmed based on bisulfite sequencing.Results: In Hep3B cells in which UCP2 mRNA was not transcribed, the promoter basal activity was significantly higher than in HT-29 or HepG2 cells in which UCP2 mRNA was transcribed. Treatment with 5-aza increased UCP2 expression in Hep3B and HT-29 cells; however, the expression in HepG2 cells was unchanged. The UCP2 promoter in Hep3B cells has numerous methylated regions compared with HT-29 and HepG2 cells.Conclusion: The results of the present study revealed that inhibition of UCP2 production in Hep3B cells was due to multiple methylation of the promoter region. Investigating the mechanism that induces UCP2 production in cancer cells is important to understand the function of UCP2, which could aid in cancer treatment.

show abstract

“…There is ample evidence from scientific research that berberine promotes upregulation of Beclin-1 and downregulation of mTOR gene. Worth of note is that the upregulation of MAP-Kinase signaling cascade and p53 gene are the key molecular process to promote autophagy in cancer cells (Wang et al, 2010 ; Zhao et al, 2019 ; Kim et al, 2020 ).…”

Section: Bioformulation Of Nanoparticles As Berberine Carriermentioning

confidence: 99%

Nanotechnology-Based Strategies for Berberine Delivery System in Cancer Treatment: Pulling Strings to Keep Berberine in Power

Iqbal¹,

Quispe

Javed

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Cancer is a multifactorial disease characterized by complex molecular landscape and altered cell pathways that results in an abnormal cell growth. Natural compounds are target-specific and pose a limited cytotoxicity; therefore, can aid in the development of new therapeutic interventions for the treatment of this versatile disease. Berberine is a member of the protoberberine alkaloids family, mainly present in the root, stem, and bark of various trees, and has a reputed anticancer activity. Nonetheless, the limited bioavailability and low absorption rate are the two major hindrances following berberine administration as only 0.5% of ingested berberine absorbed in small intestine while this percentage is further decreased to 0.35%, when enter in systemic circulation. Nano-based formulation is believed to be an ideal candidate to increase absorption percentage as at nano scale level, compounds can absorb rapidly in gut. Nanotechnology-based therapeutic approaches have been implemented to overcome such problems, ultimately promoting a higher efficacy in the treatment of a plethora of diseases. This review present and critically discusses the anti-proliferative role of berberine and the nanotechnology-based therapeutic strategies used for the nano-scale delivery of berberine. Finally, the current approaches and promising perspectives of latest delivery of this alkaloid are also critically analyzed and discussed.

show abstract

Berberine Induces p53-Dependent Apoptosis through Inhibition of DNA Methyltransferase3b in Hep3B Cells

Cited by 6 publications

References 37 publications

Effect of 5-azacytidine (5-aza) on UCP2 expression in human liver and colon cancer cells

Effect of 5-azacytidine (5-aza) on UCP2 expression in human liver and colon cancer cells

Treatment with 5-azacytidine Increases UCP2 levels in Hep3B and HT-29 Cells but Not in HepG2 Cells

Nanotechnology-Based Strategies for Berberine Delivery System in Cancer Treatment: Pulling Strings to Keep Berberine in Power

Contact Info

Product

Resources

About